Crinetics Pharmaceuticals Inc.

This study tests the long-term safety and effectiveness of an experimental drug called atumelnant (CRN04894) in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that affects hormone production. Participants must have completed a previous Crinetics…

This study tests a new drug called atumelnant in children aged 1 to 17 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely control hormone levels and reduce the need for daily steroids. About…

This study tests an experimental drug called paltusotine in 141 adults with carcinoid syndrome caused by neuroendocrine tumors. The goal is to see if it reduces daily flushing and diarrhea better than a placebo. Participants take the drug or placebo for 12 weeks and record their …

This study tests a new drug called CRN09682 in people with advanced neuroendocrine tumors and other solid tumors that have spread and are getting worse. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About 150 adults will take part…

This study tests an experimental drug called atumelnant in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. Participants will receive either atumelnant or a placebo to see if the drug can better control hormone le…

This study looks at how a new drug called atumelnant affects and is affected by other medications in healthy adults. Researchers will measure drug levels in the blood to understand interactions with liver enzymes and transporters. The goal is to gather safety and dosing informati…